News
-
-
COMMUNIQUÉ DE PRESSE
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. announces third quarter financial results for June 30, 2024, including operational highlights and future plans. Conference call/webcast today at 4:30 PM ET. View Form 10-Q at https://investors.adnas.com/sec-filings/ -
-
-
COMMUNIQUÉ DE PRESSE
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
Applied DNA Sciences, Inc. presents Linea IVT platform for enhanced mRNA production at 4th Annual mRNA-based Therapeutics Summit. Solution reduces dsRNA contamination, streamlines workflows, and boosts efficiency -
-
-
COMMUNIQUÉ DE PRESSE
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
Applied DNA Sciences announces $1.04 million contract with U.S. Defense Logistics Agency for counterfeit mitigation and product verification programs specific to FSC 5962 microcircuits. Continues support since 2014 -
-
